Binnopharm Group’s studies will be presented at the international gastroenterology congress UEGW 2024
09.08.2024
Leading pharmaceutical company Binnopharm Group will present two of its studies at UEG Week 2024, the largest international congress on gastroenterology, to be held in October in Vienna, Austria. Two abstracts (theses) prepared on the results of observational studies concerning Urdoxa®, a hepatoprotective agent with choleretic and cholelitholytic action, were included in the conference programme.
The congress will present the study “Effect of Treatment with Urdoxa® (UDCA) in Complex Therapy on the Symptoms and Quality of Life in Patients with Initial Stages of Gallstone Disease”, St. Petersburg State University. The study was aimed to evaluate the effect of ursodeoxycholic acid (UDCA) on clinical symptoms and quality of life in patients with biliary sludge (BS) in real practice. The results showed positive clinical dynamics, regression of BS with significant improvement of both physical and psychological indicators of patients’ quality of life. It was noted high safety of Urdoxa® confirmed by consistently high adherence of patients to treatment.
The second study — “Efficacy and Safety of Ursodeoxycholic Acid in Prevention and Treatment of COVID-19-Associated Liver Damage on Favipiravir Therapy”, Smolensk State Medical University, Ministry of Health of the Russian Federation (Federal State Budgetary Educational Institution of Higher Professional Education Smolensk State Medical University of the Ministry of Health of the Russian Federation). In the course of this scientific work it was found that oral administration of UDCA (Urdoxa®) resulted in faster and earlier normalisation of liver function in the form of decreased elevated levels of hepatic transaminases (ALT, AST), reduced periods of hospitalisation, restoration of liver size and bile outflow according to ultrasound scanning after 2 months of therapy.
European Gastro Week (UEG) is a European congress on the problems of diagnosis and treatment of gastrointestinal diseases, where the latest advances in the field of gastroenterology are discussed. Participation in UEG Week 2024 opens up new opportunities to develop and promote the studies that Binnopharm Group is now actively pursuing.
The congress will present the study “Effect of Treatment with Urdoxa® (UDCA) in Complex Therapy on the Symptoms and Quality of Life in Patients with Initial Stages of Gallstone Disease”, St. Petersburg State University. The study was aimed to evaluate the effect of ursodeoxycholic acid (UDCA) on clinical symptoms and quality of life in patients with biliary sludge (BS) in real practice. The results showed positive clinical dynamics, regression of BS with significant improvement of both physical and psychological indicators of patients’ quality of life. It was noted high safety of Urdoxa® confirmed by consistently high adherence of patients to treatment.
The second study — “Efficacy and Safety of Ursodeoxycholic Acid in Prevention and Treatment of COVID-19-Associated Liver Damage on Favipiravir Therapy”, Smolensk State Medical University, Ministry of Health of the Russian Federation (Federal State Budgetary Educational Institution of Higher Professional Education Smolensk State Medical University of the Ministry of Health of the Russian Federation). In the course of this scientific work it was found that oral administration of UDCA (Urdoxa®) resulted in faster and earlier normalisation of liver function in the form of decreased elevated levels of hepatic transaminases (ALT, AST), reduced periods of hospitalisation, restoration of liver size and bile outflow according to ultrasound scanning after 2 months of therapy.
European Gastro Week (UEG) is a European congress on the problems of diagnosis and treatment of gastrointestinal diseases, where the latest advances in the field of gastroenterology are discussed. Participation in UEG Week 2024 opens up new opportunities to develop and promote the studies that Binnopharm Group is now actively pursuing.
